myelin oligodendrocyte glycoprotein (MOG) antibody and antigen (Recombinant protein)
Diagnostic myelin oligodendrocyte glycoprotein (MOG) antibodies (anti-myelin oligodendrocyte glycoprotein, anti-MOG) and antigens (recombinant myelin oligodendrocyte glycoprotein (MOG) protein) for Inflammation/autoimmune/inflammatory disease MOG detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Go to Inflammation/autoimmune/inflammatory disease diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-h-MOG-Ag01 | Recombinant human MOG Protein | $3090.00 |
GMP-h-MOG-Ab01 | Anti-human MOG mouse monoclonal antibody (mAb) | $1953.00 |
GMP-h-MOG-Ab02 | Anti-human MOG mouse monoclonal antibody (mAb) | $1953.00 |
GMP-h-MOG-Ab03 | Anti-human MOG human monoclonal antibody (mAb) | $1953.00 |
GMP-h-MOG-Ab04 | Anti-human MOG human monoclonal antibody (mAb) | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Pruducts | GMP-h-MOG-Ag01 |
Product Name | Recombinant human MOG Protein |
Target/Biomarker | myelin oligodendrocyte glycoprotein (MOG) |
Alias of Target/Biomarker | BTN6, BTNL11, MOGIG2, NRCLP7 |
Expression platform | mammalian |
Isotypes | Recombinant Antigen |
Bioactivity validation | myelin oligodendrocyte glycoprotein (MOG) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MOG level test of Inflammation/autoimmune/inflammatory disease (MOG antibody disease) and related syndrome evaluation |
Products description | Recombinant Human myelin oligodendrocyte glycoprotein (MOG) protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Pruducts | GMP-h-MOG-Ab01,GMP-h-MOG-Ab02 |
Product Name | Anti-human MOG mouse monoclonal antibody (mAb) |
Target/Biomarker | myelin oligodendrocyte glycoprotein (MOG) |
Alias of Target/Biomarker | BTN6, BTNL11, MOGIG2, NRCLP7 |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Human myelin oligodendrocyte glycoprotein (MOG) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other myelin oligodendrocyte glycoprotein (MOG) antibodies in MOG level test of Inflammation/autoimmune/inflammatory disease (MOG antibody disease) and related syndrome evaluation. |
Tag | mFc |
Products description | Anti-human MOG mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other myelin oligodendrocyte glycoprotein (MOG) antibodies. |
Reconized/Reactive Species | Human |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Pruducts | GMP-h-MOG-Ab03,GMP-h-MOG-Ab04 |
Product Name | Anti-human MOG human monoclonal antibody (mAb) |
Target/Biomarker | myelin oligodendrocyte glycoprotein (MOG) |
Alias of Target/Biomarker | BTN6, BTNL11, MOGIG2, NRCLP7 |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Human myelin oligodendrocyte glycoprotein (MOG) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other myelin oligodendrocyte glycoprotein (MOG) antibodies in MOG level test of Inflammation/autoimmune/inflammatory disease (MOG antibody disease) and related syndrome evaluation. |
Tag | hFc |
Products description | Anti-human MOG mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Reconized/Reactive Species | Human |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT. |
Formulation | Supplied as a 0.2 μM filtered solution of PBS,PH7.4. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Myelin oligodendrocyte glycoprotein antibody disorders (MOGAD) is an idiopathic, inflammatory, demyelinating disease of the central nervous system (CNS). MOG is a glycoprotein uniquely expressed in oligodendrocytes in the CNS. MOG antibodies were originally thought to be involved in multiple sclerosis (MS), but subsequent studies found it to be a distinct disease. MOGAD have many similarities to neuromyelitis optica but several studies have demonstrated they have unique clinical features, treatment response, and prognosis. MOGAD were initially identified in NMOSD antibody negative patients. Pathologically NMOSD is classified as am astrocytopathy, while MOGAD are classified as oligodendrogliopathies. The MOG antibody can distinguish a spectrum of autoimmune demyelinating diseases from multiple sclerosis (MS). Testing positive for the MOG antibody indicates that a patient doesn't have classical MS. That's important because diseases associated with the MOG antibody — as well as diseases associated with the water channel aquaporin-4 (AQP4) antibody, which was discovered at Mayo Clinic — are commonly misdiagnosed as MS. Yet some MS medications have been reported to worsen diseases that mimic MS. Which patients would benefit from this antibody testing? Any patient who suddenly presents with vision loss, significant disk edema or recurrent optic neuritis should consider testing for both MOG and AQP4 antibodies. Patients who have more than one episode of optic neuritis absolutely should have testing. An optic neuritis seems to be a very common presentation of MOG.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.